Pilot Studies Work Group Jeffrey Botkin, MD, MPH.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.
Copyright © Healthcare Quality Quest, Proposed standards for a national clinical audit — How we got involved and what we have learned.
Participation Requirements for a Patient Representative.
1 Orientation For Reviews of Initial Credentialing Proposals Ron Briel, Program Manager Licensure Unit Division of Public Health Department of Health &
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Protecting the Privacy of Family Members in Survey and Pedigree Research Jeffrey R. Botkin, MD, MPH University of Utah.
Small Starts: Promise Deferred for Streetcars Jeffrey F. Boothe 2099 Pennsylvania Avenue, NW Suite 100 Washington, DC (202)
Decision Criteria and Process Advisory Committee on Heritable Disorders in Newborns and Children February 26-27, 2009.
NBSTRN Update NCC/RC PI/PD Meeting November 19, 2010 Michael Watson.
Participation Requirements for a Guideline Panel PGIN Representative.
Draft manuscript: “Implementing Point-of-Care Newborn Screening” From the SACHDNC Follow-up & Treatment Sub-committee 1/27/2012 Nancy S. Green, MD Associate.
The Reorganization of University Advancement Scott C. Warrington, VP for UA.
Family Resource Center Association January 2015 Quarterly Meeting.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Special Topics in IND Regulation
Grant Writing1 Grant Writing Lecture What are the major types of grants available in mental health research? What is the process of grant preparation and.
NIH Proposed Use of a Central IRB (C-IRB) for NIH-funded multi-site studies Committee on Clinical Research January 26,
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
DACHDNC MEETING JANUARY 16, 2014 Education and Training Subcommittee Don Bailey, Chair Beth Tarini, Co-Chair.
Effectively Responding to Award Solicitations Objective Identify elements of a government solicitation package. Respond more effectively to government.
Safeguarding Animal Health 1 Proposed BSE Comprehensive Rule: A New Approach to BSE Rulemaking Dr. Christopher Robinson Assistant Director, NCIE BSE Comprehensive.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
Breastfeeding and Environmental Change: A Focus on Maternity Care Practices The Massachusetts Experience Rachel Colchamiro, MPH, RD, LDN, CLC State Breastfeeding.
Secretary’s Advisory Committee on Heritable Disorders of Newborns and Children September 22, 2011 Newborn Screening Translational Research Network (NBSTRN)
Education and Training Subcommittee Report SACHDNC Advisory Committee Meeting May 17-18, 2012.
Avoiding the Pitfalls of an IRB Submission Chris Ayres Chair, Institutional Review Board Social & Behavioral Science & Chair, Department of Kinesiology,
Treuman Katz Center for Pediatric Bioethics Conference Banking Biological Samples for Pediatric Research Jeffrey R. Botkin, M.D., M.P.H. Professor.
Federal Emphasis on Accountability in Higher Education and Regional Accreditation Processes Carla D. Sanderson Commissioner, Southern Association of Colleges.
Water Supply Planning Initiative State Water Commission November 22, 2004.
Challenges with conducting NBS pilot studies Jeffrey R. Botkin, M.D., M.P.H. Professor of Pediatrics Chief, Division of Medical Ethics and Humanities Associate.
Newborn Screening Translational Research Network Virtual Repository of Dried Blood Spots Investigator Demonstration February 16, 2012 Call in Number: (470)
Tips for Researchers on Completing the Data Analysis Section of the IRB Application Don Allensworth-Davies, MSc Statistical Manager, Data Coordinating.
Ethical and Regulatory Considerations in Research using Residual Specimens Jeffrey R. Botkin, M.D., M.P.H. Professor of Pediatrics and Medical Ethics Associate.
The Secretary’s Advisory Committee on Human Research Protections (SACHRP): Recommendations Regarding the Newborn Screening Reauthorization Act of 2014.
Arizona Early Intervention Program IDEA 2011 Requirements -Screening-
Condition Review Process Report - Update Alex R. Kemper, MD, MPH, MS May 18, 2012.
Evidence Review Group: Past to Present James M. Perrin, MD Professor of Pediatrics, Harvard Medical School MGH Center for Child and Adolescent Health Policy.
Title III Notice of Proposed Interpretations Presentation for LEP SCASS/CCSSO May 7, 2008.
New Draft Guidance for Multiplex Tests Elizabeth Mansfield and Michele Schoonmaker Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) CDRH/FDA.
Recommendation to ACHDNC for Newborn Screening for X-linked Adrenoleukodystrophy Fred Lorey, Ph.D. Don Bailey, Ph.D. Liaisons to the Condition Review Workgroup.
Overview of FDA's Regulatory Framework for PET Drugs
Mark Ruane ERCOT Vice President of Credit and Enterprise Risk Management Dodd-Frank Act Exemption Update Technical Advisory Committee May 5, 2011 Bill.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Update on SACHDNC Administrative Processes Sara Copeland, MD Chief, Genetics Services Branch Designated Federal Officer Secretary’s Advisory Committee.
Pompe Disease Evidence Evaluation Michael Watson, PhD, on behalf of Piero Rinaldo, MD, PhD, and the Decision-Making Workgroup October 1, 2008.
Newborn Screening Translational Research Network Virtual Repository of Dried Blood Spots Investigator Demonstration March 15, 2012 Call in Number: (415)
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
Moving the Evidence Review Process Forward Alex R. Kemper, MD, MPH, MS September 22, 2011.
Recommendation Methods Advisory Committee on Heritable Disorders and Genetic Diseases of Newborns and Children Ned Calonge, M.D., M.P.H.
HIPAA and Human Subjects Research IRB Member CE May 2014 Slideshow by Sean Horkheimer.
The Impact of Obtaining Documented Informed Consent on MS/MS Screening L.A. Faulkner 1, L.B. Feuchtbaum 2, M. Hanlon 1, F.W. Lorey 2, K. Velazquez 2, and.
The Role of the Internal and External Evaluators in Student Assessment Arthur Brown Advisor to the Quality Assurance and Accreditation Project Republic.
Medical Research in Times of Bioterrorism - OHRP’s Perspective Michael A. Carome, M.D. Associate Director for Regulatory Affairs Office for Human Research.
Kansas City Power & Light and KCP&L Greater Missouri Operations – Suggestions for Chapter 22 Revisions Missouri Public Service Commission Meeting Aug 31,
IRB Presentation to the Pediatric Ethics Subcommittee of the FDA regarding “Gonadotropin Releasing Hormone (GnRH) Agonist Test in Disorders of Puberty”
Christine Yalda, J.D., Ph.D. Chair, Human Research Review Committee Grand Valley State University.
FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.
Stages of Research and Development
University of Central Florida Office of Research & Commercialization
FDA’s IDE Decisions and Communications
Research on human biological materials: Lithuanian perspective
Working with your AoA Project Officer
Overview - Introduction
Overview - Introduction
Accountability and Internal Controls – Best Practices
University of Central Florida Office of Research & Commercialization
Assessing Academic Programs at IPFW
Development Plans: Study Design and Dose Selection
Charter School Legislation HB 1390 and SB 737.
Presentation transcript:

Pilot Studies Work Group Jeffrey Botkin, MD, MPH

Pilot Studies Work Group Membership – Andrea Atherton – Don Bailey – Joe Bocchini – Jeff Botkin – Anne Comeau – Carla Cuthbert – Kellie Kelm – Dieter Matern – Mark McCann – Melissa Parisi – Scott Shone – Tiina Urv – Mike Watson

Pilot Studies General recognition that evidence review process requires evidence Challenges – Rare conditions – Population based research is complex and expensive – Section 12 of the NBSSLRA requires informed consent for use of DBS

Pilot Studies Consent issues – Section 12 requires parental consent for use of DBS – Eliminates the ability to conduct federally funded research that involves adding a new screening test on a pilot basis on an opt-out basis or with a simplified consent process – Consent processes reduce uptake substantially

Pilot Studies Notice of Proposed Rule Making for human subjects regulations is pending Comment period followed by drafting of final rules For the time being, “pilot studies” in the context may require either consent or to be conducted through state mandated systems (would not be federally funded research)

Charge to the Committee Recognize and support current efforts regarding pilot studies and evaluation Identify other resources that could support pilot studies and evaluation Identify the information required by the Committee to move a nominated condition into the evidence review process (i.e., define the minimum pilot study data required for a condition to be accepted for evidence review)

Charge to the Committee Recognize and support current efforts regarding pilot studies and evaluation Identify other resources that could support pilot studies and evaluation Identify the information required by the Committee to move a nominated condition into the evidence review process (i.e., define the minimum pilot study data required for a condition to be accepted for evidence review)

Focus The question is what data are the minimal necessary to move a nominated condition to the evidence review process. NOT what evidence is necessary to approve a condition for the RUSP

ACHDNC Nomination Form For a nominated condition to be considered there are 3 core requirements 1.Validation of the laboratory test 2.Widely available confirmatory testing with a sensitive and specific diagnostic test 3.A prospective population based pilot study

ACHDNC Nomination Form For a nominated condition to be considered there are 3 core requirements 1.Validation of the laboratory test 2.Widely available confirmatory testing with a sensitive and specific diagnostic test 3.A prospective population based pilot study

ACHDNC Track Record The absence of a “pilot study” has been a consistent fault identified in applications in decisions not to move a condition to evidence review Additional clarity on the nature of the “pilot study” is necessary

“Pilot Studies” Used in the literature for a variety of types of studies in this domain – Test validation studies – Testing of anonymous dried blood spots The term “pilot study” is non-specific Better clarity in the type of study necessary to move a nomination forward

Proposed requirements How does a screening test perform on a population-based sample in terms of clinical validity? Existing requirement – A prospective population based pilot study Proposed requirement – “A prospective population based evaluation of newborn screening and patient identification”

Proposed Requirement Stipulations – Newborns screened should be identifiable and their clinical status evaluated to determine the clinical validity of the screening test result – At least one affected newborn should be detected through population screening – The evaluation need not demonstrate clinical utility as long as other data are submitted to address the utility of screening – The screening evaluation should be conducted in an appropriate population, that is, one that adequately represents the US population that will be screening in NBS programs for the condition at hand

Process What process should the ACHDNC use to determine if the criteria have been met to move a condition to evidence review?